Non-small cell lung cancer, BRAF-mutated

Section editor
	Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

3 regimens on this page 3 variants on this page

Advanced or metastatic disease, first-line

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose

Study	Evidence
Planchard et al. 2017 (BRF113928-untreated)	Phase II (RT)

Biomarker Eligibility Criteria

• Biomarker: BRAF V600E

Chemotherapy

• Dabrafenib (Tafinlar) 150 mg PO twice per day
• Trametinib (Mekinist) 2 mg PO once per day

Continued indefinitely

References

1. BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed

Advanced or metastatic disease, previously treated, BRAF inhibitor-naive

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose

Study	Evidence
Planchard et al. 2016 (BRF113928-treated)	Phase II (RT)

All enrolled patients had progressed on 1 to 3 prior regimens.

Biomarker Eligibility Criteria

• Biomarker: BRAF V600E

Chemotherapy

• Dabrafenib (Tafinlar) 150 mg PO twice per day
• Trametinib (Mekinist) 2 mg PO once per day

Continued indefinitely

References

1. BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to PMC article PubMed